Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 12/20 | 0.55 |
| ▸ | DRD2 | P14416 | 8/20 | 0.55 |
| ▸ | DRD3 | P35462 | 6/20 | 0.55 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701280 | 0.79 | DRD4 (0.75) | DRD4DRD2DRD3KMT2AALDH1A1 | |
| SCHEMBL2744707 | 0.78 | ALDH1A1 (0.61) | DRD4GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL27563358 | 0.76 | — | — | |
| SCHEMBL3968181 | 0.76 | DRD2 (0.73) | DRD4DRD2DRD3HTR1AALOX15 | |
| SCHEMBL29499599 | 0.76 | GRIN2D (0.59) | DRD4DRD2DRD3GRIN2DGRIN3B | |
| SCHEMBL19998348 | 0.76 | GRIN2D (0.59) | DRD4DRD2DRD3GRIN2DGRIN3B | |
| SCHEMBL2744468 | 0.75 | ALDH1A1 (0.53) | DRD4DRD2DRD3GRIN2DGRIN3B | |
| SCHEMBL1682870 | 0.74 | GAA (0.57) | DRD4DRD2DRD3GRIN2DGRIN3B | |
| SCHEMBL2744105 | 0.74 | CASP1 (0.52) | DRD4DRD2DRD3GRIN2DGRIN3B | |
| SCHEMBL2744864 | 0.74 | HRH3 (0.60) | DRD4GRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-01-15 | — | — | US | claimed |
| EP-1289982-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | claimed |
| WO-2001096327-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | claimed |
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-01-15 | — | — | US | disclosed |
| EP-1289982-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096327-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | APOB, APOL1, TTR | DRD4 3005/4885DRD2 3054/4885DRD3 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.